Canadian AI Biotechnology Company

Accelerating Drug Discovery Through Artificial Intelligence

Living In Silico combines artificial intelligence, Graph Neural Networks, Digital Twin technology, and computational biology to accelerate antimicrobial drug discovery and sustainable biotechnology — transforming how we identify and develop next-generation therapeutics.

Explore Our Platforms Our Technology

Our AI Platforms

Three Platforms. One Mission.

AI-powered prediction platforms targeting the world's most dangerous drug-resistant pathogens, built on Graph Neural Networks and Digital Twin technology.

TB-Predict™

Tuberculosis Drug Discovery

AI-powered prediction platform for discovering therapeutics targeting Mycobacterium tuberculosis, the causative agent of tuberculosis.

Graph Neural Networks
Digital Twin Technology
Molecular Docking
Compound Prioritization

KB-Predict™

Klebsiella pneumoniae Discovery

AI platform focused on predicting compounds active against drug-resistant Klebsiella pneumoniae, a WHO high-priority pathogen.

Drug-Resistant Pathogen Prediction
Machine Learning
High-Throughput Screening
Virtual Compound Ranking

Pseudo-Predict™

Pseudomonas aeruginosa Targeting

AI platform targeting Pseudomonas aeruginosa, one of the WHO's highest-priority multidrug-resistant pathogens.

Virtual Screening
Molecular Simulation
AI-Driven Therapeutic Prediction
Drug Discovery Pipeline

Why AI-Driven Discovery?

Traditional vs AI-Driven Discovery

Graph Neural Networks transform antimicrobial discovery by learning directly from molecular structure, replacing costly trial-and-error with intelligent prioritization.

Traditional Drug Discovery

Random screening
High laboratory costs
Low hit rate
Slow discovery timelines
Months to years

Living In Silico

AI-guided compound prioritization
Millions of molecules screened
Higher probability of active compounds
Faster decision making
Reduced experimental cost

Corporate Updates

Latest News

Milestone

Corporation Successfully Revived — May 2026

Living In Silico Inc. has been successfully revived with active corporate status restored, positioning the company for commercialization and strategic growth.

Growth

Commercialization Readiness

The company is advancing toward commercialization of its AI drug discovery platforms and SURF-AC™ biosurfactant technology, with active funding opportunities and strategic partnerships.